SciELO - Scientific Electronic Library Online

 
vol.145 número2Leiomiomatosis benigna metastásica: reporte de caso clínicoRetracción palpebral de causa neurológica: Presentación de tres pacientes, interpretación patogénica índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

PALMA, Estefanía et al. Shock as an adverse reaction to rituximab: Case report. Rev. méd. Chile [online]. 2017, vol.145, n.2, pp.260-263. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872017000200015.

Rituximab is a plausible alternative first-line treatment of ANCA-associated vasculitis. Adverse effects related to its infusion are common and usually have a benign course. However, there have been reports of refractory cardiogenic shock simulating septic shock. We report an 81-year-old male with the diagnosis of ANCA associated vasculitis. Rituximab 500 mg was administered intravenously for a relapse. The infusion proceeded without incident. However, 24 hours after its administration the patient began with fever, chills, coughing and strong malaise. The patient was transferred to the critical patient unit where a septic shock was suspected and resuscitative measures were started. However, the fast response to moderate doses of vasoactive drugs and complementary tests did not support an infectious etiology for the shock. Antimicrobials were discontinued and systemic corticosteroids were maintained, achieving remission of the symptoms. Shock as an unusual adverse reaction to Rituximab was suspected.

Palabras clave : Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Drug-Related Side Effects and Adverse Reactions; Rituximab; Shock.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons